Novel molecular imaging in lung and pleural diseases

Respirology

Volumn 16, Issue 8, 2011, Pages 1173-1188

  Francis, Roslyn ^a,b   Segard, Tatiana ^a   Morandeau, Laurence ^a  

^a SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

molecular imaging; positron emission tomography; prognosis; radioisotope; thoracic neoplasm

Indexed keywords

1 [2 FLUORO 1 (HYDROXYMETHYL)ETHOXY]METHYL 2 NITROIMIDAZOLE F 18; 1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; 3' FLUOROTHYMIDINE F 18; ALPHA METHYLTYROSINE F 18; ANNEXIN V TC 99M; CETUXIMAB ZR 89; CHOLINE C 11; CISPLATIN; COPPER DIACETYL BIS(N 4 METHYLTHIOSEMICARBAZONE); ERLOTINIB; FLUORODEOXYGLUCOSE; GEFITINIB; GEMCITABINE; METHIONINE C 11; OCTREOTATE GA 68; PENTETREOTIDE IN 111; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ADENOCARCINOMA; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER RESISTANCE; CELL PROLIFERATION; DIAGNOSTIC ACCURACY; DISEASE SEVERITY; HUMAN; HYPOXIA; LUNG DISEASE; LUNG NODULE; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MESOTHELIOMA; MOLECULAR IMAGING; MOLECULAR PROBE; PLEURA DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT PLANNING; TREATMENT RESPONSE; TUMOR VOLUME;

FEMALE; FLUORODEOXYGLUCOSE F18; GAMMA RAYS; HUMANS; LUNG DISEASES; LUNG NEOPLASMS; MALE; MOLECULAR IMAGING; PLEURAL DISEASES; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY;

EID: 80155180537     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/j.1440-1843.2011.02059.x     Document Type: Review

References (119)

1. Brown RS, Leung JY, Kison PV, et al,. Glucose transporters and FDG uptake in untreated primary human non-small cell lung cancer. J. Nucl. Med. 1999; 40: 556-65. (Pubitemid 29171796)
2. Teirstein AS, Machac J, Almeida O, et al,. Results of 188 whole-body fluorodeoxyglucose positron emission tomography scans in 137 patients with sarcoidosis. Chest 2007; 132: 1949-53.
3. Keijsers RG, Grutters JC, Thomeer M, et al,. Imaging the inflammatory activity of sarcoidosis: sensitivity and inter observer agreement of 67Ga imaging and 18F-FDG PET. Q. J. Nucl. Med. Mol. Imaging 2011; 55: 66-71.
4. Braun JJ, Kessler R, Constantinesco A, et al,. 18F-FDG PET/CT in sarcoidosis management: review and report of 20 cases. Eur. J. Nucl. Med. Mol. Imaging 2008; 35: 1537-43.
5. Basu S, Saboury B, Werner T, et al,. Clinical utility of FDG-PET and PET/CT in non-malignant thoracic disorders. Mol. Imaging Biol. 2010; Epub ahead of print.
6. Wahidi MM, Govert JA, Goudar RK, et al,. Evidence for the treatment of patients with pulmonary nodules: when is it lung cancer?: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007; 132: 94S-107S. (Pubitemid 47502802)
7. Nomori H, Watanabe K, Ohtsuka T, et al,. Evaluation of F-18 fluorodeoxyglucose (FDG) PET scanning for pulmonary nodules less than 3 cm in diameter, with special reference to the CT images. Lung Cancer 2004; 45: 19-27. (Pubitemid 38757828)
8. Matthies A, Hickeson M, Cuchiara A, et al,. Dual time point 18F-FDG PET for the evaluation of pulmonary nodules. J. Nucl. Med. 2002; 43: 871-5. (Pubitemid 34747808)
9. Alkhawaldeh K, Bural G, Kumar R, et al,. Impact of dual-time-point (18)F-FDG PET imaging and partial volume correction in the assessment of solitary pulmonary nodules. Eur. J. Nucl. Med. Mol. Imaging 2008; 35: 246-52.
10. Macdonald K, Searle J, Lyburn I,. The role of dual time point FDG PET imaging in the evaluation of solitary pulmonary nodules with an initial standard uptake value less than 2.5. Clin. Radiol. 2011; 66: 244-50.
11. Gambhir SS, Shepherd JE, Shah BD, et al,. Analytical decision model for the cost-effective management of solitary pulmonary nodules. J. Clin. Oncol. 1998; 16: 2113-25. (Pubitemid 28265048)
12. Facey K, Bradbury I, Laking G, et al,. Overview of the clinical effectiveness of positron emission tomography imaging in selected cancers. Health Technol. Assess. 2007; 11: iii-iv, xi-267.
13. Toloza EM, Harpole L, McCrory DC,. Noninvasive staging of non-small cell lung cancer: a review of the current evidence. Chest 2003; 123: 137S-46S. (Pubitemid 36135711)
14. Silvestri GA, Gould MK, Margolis ML, et al,. Noninvasive staging of non-small cell lung cancer: ACCP evidenced-based clinical practice guidelines (2nd edition). Chest 2007; 132: 178S-201S. (Pubitemid 47502807)
15. Cerfolio RJ, Ojha B, Bryant AS, et al,. The accuracy of integrated PET-CT compared with dedicated PET alone for the staging of patients with nonsmall cell lung cancer. Ann. Thorac. Surg. 2004; 78: 1017-23. discussion-23. (Pubitemid 39164825)
16. Lardinois D, Weder W, Hany TF, et al,. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N. Engl. J. Med. 2003; 348: 2500-7. (Pubitemid 36706537)
17. Baum RP, Hellwig D, Mezzetti M,. Position of nuclear medicine modalities in the diagnostic workup of cancer patients: lung cancer. Q. J. Nucl. Med. Mol. Imaging 2004; 48: 119-42. (Pubitemid 39248300)
18. van Tinteren H, Hoekstra OS, Smit EF, et al,. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet 2002; 359: 1388-93.
19. MacManus MP, Hicks RJ, Matthews JP, et al,. High rate of detection of unsuspected distant metastases by PET in apparent stage III non-small-cell lung cancer: implications for radical radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 2001; 50: 287-93. (Pubitemid 32472257)
20. Kalff V, Hicks RJ, MacManus MP, et al,. Clinical impact of (18)F fluorodeoxyglucose positron emission tomography in patients with non-small-cell lung cancer: a prospective study. J. Clin. Oncol. 2001; 19: 111-18. (Pubitemid 32063487)
21. Bunyaviroch T, Coleman RE,. PET evaluation of lung cancer. J. Nucl. Med. 2006; 47: 451-69. (Pubitemid 46768488)
22. Brink I, Schumacher T, Mix M, et al,. Impact of [18F]FDG-PET on the primary staging of small-cell lung cancer. Eur. J. Nucl. Med. Mol. Imaging 2004; 31: 1614-20. (Pubitemid 40104607)
23. Fischer BM, Mortensen J, Langer SW, et al,. A prospective study of PET/CT in initial staging of small-cell lung cancer: comparison with CT, bone scintigraphy and bone marrow analysis. Ann. Oncol. 2007; 18: 338-45. (Pubitemid 46323103)
24. Niho S, Fujii H, Murakami K, et al,. Detection of unsuspected distant metastases and/or regional nodes by FDG-PET [corrected] scan in apparent limited-disease small-cell lung cancer. Lung Cancer 2007; 57: 328-33. (Pubitemid 47285426)
25. Vansteenkiste JF, Stroobants SG, Dupont PJ, et al,. Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: an analysis of 125 cases. Leuven Lung Cancer Group. J. Clin. Oncol. 1999; 17: 3201-6. (Pubitemid 29470652)
26. Ahuja V, Coleman RE, Herndon J, et al,. The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma. Cancer 1998; 83: 918-24. (Pubitemid 28401925)
27. Okereke IC, Gangadharan SP, Kent MS, et al,. Standard uptake value predicts survival in non-small cell lung cancer. Ann. Thorac. Surg. 2009; 88: 911-16.
28. Hoang JK, Hoagland LF, Coleman RE, et al,. Prognostic value of fluorine-18 fluorodeoxyglucose positron emission tomography imaging in patients with advanced-stage non-small-cell lung carcinoma. J. Clin. Oncol. 2008; 26: 1459-64.
29. Paesmans M, Berghmans T, Dusart M, et al,. Primary tumor standardized uptake value measured on fluorodeoxyglucose positron emission tomography is of prognostic value for survival in non-small cell lung cancer: update of a systematic review and meta-analysis by the European Lung Cancer Working Party for the International Association for the Study of Lung Cancer Staging Project. J. Thorac. Oncol. 2010; 5: 612-19.
30. Lee P, Weerasuriya DK, Lavori PW, et al,. Metabolic tumor burden predicts for disease progression and death in lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 2007; 69: 328-33. (Pubitemid 47380105)
31. MacManus M, Hicks RJ,. The use of positron emission tomography (PET) in the staging/evaluation, treatment, and follow-up of patients with lung cancer: a critical review. Int. J. Radiat. Oncol. Biol. Phys. 2008; 72: 1298-306.
32. De Ruysscher D, Wanders S, Minken A, et al,. Effects of radiotherapy planning with a dedicated combined PET-CT-simulator of patients with non-small cell lung cancer on dose limiting normal tissues and radiation dose-escalation: a planning study. Radiother. Oncol. 2005; 77: 5-10. (Pubitemid 41503382)
33. van Baardwijk A, Wanders S, Boersma L, et al,. Mature results of an individualized radiation dose prescription study based on normal tissue constraints in stages I to III non-small-cell lung cancer. J. Clin. Oncol. 2010; 28: 1380-6.
34. Aerts HJ, van Baardwijk AA, Petit SF, et al,. Identification of residual metabolic-active areas within individual NSCLC tumours using a pre-radiotherapy (18)fluorodeoxyglucose-PET-CT scan. Radiother. Oncol. 2009; 91: 386-92.
35. Therasse P, Arbuck SG, Eisenhauer EA, et al,. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 2000; 92: 205-16.
36. MacManus MP, Hicks RJ, Matthews JP, et al,. Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. J. Clin. Oncol. 2003; 21: 1285-92. (Pubitemid 46606405)
37. Hicks RJ,. Role of 18F-FDG PET in assessment of response in non-small cell lung cancer. J. Nucl. Med. 2009; 50 (Suppl. 1): 31S-42S.
38. Larson SM, Erdi Y, Akhurst T, et al,. Tumor treatment response based on visual and quantitative changes in global tumor glycolysis using PET-FDG imaging. The visual response score and the change in total lesion glycolysis. Clin. Positron Imaging 1999; 2: 159-71.
39. Nahmias C, Hanna WT, Wahl LM, et al,. Time course of early response to chemotherapy in non-small cell lung cancer patients with 18F-FDG PET/CT. J. Nucl. Med. 2007; 48: 744-51. (Pubitemid 47604974)
40. Ryu JS, Choi NC, Fischman AJ, et al,. FDG-PET in staging and restaging non-small cell lung cancer after neoadjuvant chemoradiotherapy: correlation with histopathology. Lung Cancer 2002; 35: 179-87. (Pubitemid 34136096)
41. Choi NC, Fischman AJ, Niemierko A, et al,. Dose-response relationship between probability of pathologic tumor control and glucose metabolic rate measured with FDG PET after preoperative chemoradiotherapy in locally advanced non-small-cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 2002; 54: 1024-35. (Pubitemid 35292613)
42. Cerfolio RJ, Bryant AS, Winokur TS, et al,. Repeat FDG-PET after neoadjuvant therapy is a predictor of pathologic response in patients with non-small cell lung cancer. Ann. Thorac. Surg. 2004; 78: 1903-9; discussion 9. (Pubitemid 39556258)
43. Yamamoto Y, Nishiyama Y, Monden T, et al,. Correlation of FDG-PET findings with histopathology in the assessment of response to induction chemoradiotherapy in non-small cell lung cancer. Eur. J. Nucl. Med. Mol. Imaging 2006; 33: 140-7. (Pubitemid 43152880)
44. MacManus MP, Hicks RJ, Matthews JP, et al,. Metabolic (FDG-PET) response after radical radiotherapy/chemoradiotherapy for non-small cell lung cancer correlates with patterns of failure. Lung Cancer 2005; 49: 95-108. (Pubitemid 40798098)
45. Eschmann SM, Friedel G, Paulsen F, et al,. 18F-FDG PET for assessment of therapy response and preoperative re-evaluation after neoadjuvant radio-chemotherapy in stage III non-small cell lung cancer. Eur. J. Nucl. Med. Mol. Imaging 2007; 34: 463-71. (Pubitemid 46426996)
46. Tanvetyanon T, Eikman EA, Sommers E, et al,. Computed tomography response, but not positron emission tomography scan response, predicts survival after neoadjuvant chemotherapy for resectable non-small-cell lung cancer. J. Clin. Oncol. 2008; 26: 4610-16.
47. Boellaard R, O'Doherty MJ, Weber WA, et al,. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur. J. Nucl. Med. Mol. Imaging 2010; 37: 181-200.
48. Wahl RL, Jacene H, Kasamon Y, et al,. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J. Nucl. Med. 2009; 50 (Suppl. 1): 122S-50S.
49. Kubota R, Yamada S, Kubota K, et al,. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J. Nucl. Med. 1992; 33: 1972-80.
50. Yamada Y, Uchida Y, Tatsumi K, et al,. Fluorine-18-fluorodeoxyglucose and carbon-11-methionine evaluation of lymphadenopathy in sarcoidosis. J. Nucl. Med. 1998; 39: 1160-6. (Pubitemid 28326144)
51. Shreve PD, Anzai Y, Wahl RL,. Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. Radiographics 1999; 19: 61-77; quiz 150-1.
52. Rasey JS, Grierson JR, Wiens LW, et al,. Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J. Nucl. Med. 2002; 43: 1210-17. (Pubitemid 34988769)
53. Sherley JL, Kelly TJ,. Regulation of human thymidine kinase during the cell cycle. J. Biol. Chem. 1988; 263: 8350-8.
54. Shields AF, Grierson JR, Dohmen BM, et al,. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat. Med. 1998; 4: 1334-6. (Pubitemid 28512118)
55. Dittmann H, Dohmen BM, Paulsen F, et al,. [18F]FLT PET for diagnosis and staging of thoracic tumours. Eur. J. Nucl. Med. Mol. Imaging 2003; 30: 1407-12. (Pubitemid 37247960)
56. Vesselle H, Grierson J, Muzi M, et al,. In vivo validation of 3′deoxy-3′-[(18)F]fluorothymidine ([(18)F]FLT) as a proliferation imaging tracer in humans: correlation of [(18)F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors. Clin. Cancer Res. 2002; 8: 3315-23. (Pubitemid 35340704)
57. Buck AK, Halter G, Schirrmeister H, et al,. Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG. J. Nucl. Med. 2003; 44: 1426-31. (Pubitemid 39663355)
58. Yap CS, Czernin J, Fishbein MC, et al,. Evaluation of thoracic tumors with 18F-fluorothymidine and 18F-fluorodeoxyglucose-positron emission tomography. Chest 2006; 129: 393-401. (Pubitemid 43289860)
59. Yamamoto Y, Nishiyama Y, Ishikawa S, et al,. Correlation of 18F-FLT and 18F-FDG uptake on PET with Ki-67 immunohistochemistry in non-small cell lung cancer. Eur. J. Nucl. Med. Mol. Imaging 2007; 34: 1610-16. (Pubitemid 47476919)
60. Cobben DC, Elsinga PH, Hoekstra HJ, et al,. Is 18F-3′-fluoro- 3′-deoxy-L-thymidine useful for the staging and restaging of non-small cell lung cancer? J. Nucl. Med. 2004; 45: 1677-82. (Pubitemid 47618474)
61. Buck AK, Hetzel M, Schirrmeister H, et al,. Clinical relevance of imaging proliferative activity in lung nodules. Eur. J. Nucl. Med. Mol. Imaging 2005; 32: 525-33. (Pubitemid 41214194)
62. Yamamoto Y, Nishiyama Y, Kimura N, et al,. Comparison of (18)F-FLT PET and (18)F-FDG PET for preoperative staging in non-small cell lung cancer. Eur. J. Nucl. Med. Mol. Imaging 2008; 35: 236-45.
63. Yang W, Zhang Y, Fu Z, et al,. Imaging of proliferation with 18F-FLT PET/CT versus 18F-FDG PET/CT in non-small-cell lung cancer. Eur. J. Nucl. Med. Mol. Imaging 2010; 37: 1291-9.
64. Ullrich RT, Zander T, Neumaier B, et al,. Early detection of erlotinib treatment response in NSCLC by 3′-deoxy-3′-[F]-fluoro-L-thymidine ([F]FLT) positron emission tomography (PET). PLoS ONE 2008; 3: e3908.
65. Sohn HJ, Yang YJ, Ryu JS, et al,. [18F] fluorothymidine positron emission tomography before and 7 days after gefitinib treatment predicts response in patients with advanced adenocarcinoma of the lung. Clin. Cancer Res. 2008; 14: 7423-9.
66. Mileshkin L, Hicks RJ, Hughes BG, et al,. Changes in FDG- and FLT-PET imaging in patients with non-small cell lung cancer treated with erlotinib. Clin. Cancer Res. 2011; 17: 3304-15.
67. Zander T, Scheffler M, Nogova L, et al,. Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [(18)F]fluorodeoxyglucose and [(18)F]fluorothymidine positron emission tomography. J. Clin. Oncol. 2011; 29: 1701-8.
68. Le QT, Chen E, Salim A, et al,. An evaluation of tumor oxygenation and gene expression in patients with early stage non-small cell lung cancers. Clin. Cancer Res. 2006; 12: 1507-14.
69. Tatum JL, Kelloff GJ, Gillies RJ, et al,. Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int. J. Radiat. Biol. 2006; 82: 699-757. (Pubitemid 44832019)
70. Overgaard J,. Hypoxic radiosensitization: adored and ignored. J. Clin. Oncol. 2007; 25: 4066-74. (Pubitemid 47492951)
71. Lee ST, Scott AM,. Hypoxia positron emission tomography imaging with 18f-fluoromisonidazole. Semin. Nucl. Med. 2007; 37: 451-61. (Pubitemid 47498258)
72. Eschmann SM, Paulsen F, Reimold M, et al,. Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. J. Nucl. Med. 2005; 46: 253-60. (Pubitemid 43073432)
73. Gagel B, Reinartz P, Demirel C, et al,. [18F] fluoromisonidazole and [18F] fluorodeoxyglucose positron emission tomography in response evaluation after chemo-/radiotherapy of non-small-cell lung cancer: a feasibility study. BMC Cancer 2006; 6: 51-8.
74. Cherk MH, Foo SS, Poon AM, et al,. Lack of correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in non-small cell lung cancer assessed by 18F-fluoromisonidazole and 18F-FDG PET. J. Nucl. Med. 2006; 47: 1921-6. (Pubitemid 47544979)
75. Koh WJ, Bergman KS, Rasey JS, et al,. Evaluation of oxygenation status during fractionated radiotherapy in human nonsmall cell lung cancers using [F-18]fluoromisonidazole positron emission tomography. Int. J. Radiat. Oncol. Biol. Phys. 1995; 33: 391-8.
76. Vera P, Bohn P, Edet-Sanson A, et al,. Simultaneous positron emission tomography (PET) assessment of metabolism with (1)F-fluoro-2-deoxy-d-glucose (FDG), proliferation with (1)F-fluoro-thymidine (FLT), and hypoxia with (1)fluoro-misonidazole (F-miso) before and during radiotherapy in patients with non-small-cell lung cancer (NSCLC): a pilot study. Radiother. Oncol. 2011; 98: 109-16.
77. Postema EJ, McEwan AJ, Riauka TA, et al,. Initial results of hypoxia imaging using 1-alpha-D: -(5-deoxy-5-[18F]-fluoroarabinofuranosyl)-2- nitroimidazole (18F-FAZA). Eur. J. Nucl. Med. Mol. Imaging 2009; 36: 1565-73.
78. Yasuda H, Kaneta T, Takai Y, et al,. Tumor hypoxia imaging with [F-18] fluoronitroimidazole in non-small-cell lung cancer. J. Am. Geriatr. Soc. 2007; 55: 1142-4. (Pubitemid 47024613)
79. Li L, Hu M, Zhu H, et al,. Comparison of 18F-fluoroerythronitroimidazole and 18F-fluorodeoxyglucose positron emission tomography and prognostic value in locally advanced non-small-cell lung cancer. Clin. Lung Cancer 2010; 11: 335-40.
80. Dehdashti F, Mintun MA, Lewis JS, et al,. In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM. Eur. J. Nucl. Med. Mol. Imaging 2003; 30: 844-50. (Pubitemid 36734203)
81. Kuge Y, Zhao S, Takei T, et al,. Molecular imaging of apoptosis with radio-labeled annexin A5 focused on the evaluation of tumor response to chemotherapy. Anticancer. Agents Med. Chem. 2009; 9: 1003-11.
82. Belhocine T, Steinmetz N, Hustinx R, et al,. Increased uptake of the apoptosis-imaging agent (99m)Tc recombinant human annexin V in human tumors after one course of chemotherapy as a predictor of tumor response and patient prognosis. Clin. Cancer Res. 2002; 8: 2766-74. (Pubitemid 35025718)
83. Kartachova M, Haas RL, Olmos RA, et al,. In vivo imaging of apoptosis by 99mTc-annexin V scintigraphy: visual analysis in relation to treatment response. Radiother. Oncol. 2004; 72: 333-9. (Pubitemid 39265388)
84. Kartachova M, van Zandwijk N, Burgers S, et al,. Prognostic significance of 99mTc HYNIC-rh-annexin V scintigraphy during platinum-based chemotherapy in advanced lung cancer. J. Clin. Oncol. 2007; 25: 2534-9. (Pubitemid 47041226)
85. Kartachova MS, Valdes Olmos RA, Haas RL, et al,. 99mTc-HYNIC-rh-annexin-V scintigraphy: visual and quantitative evaluation of early treatment-induced apoptosis to predict treatment outcome. Nucl. Med. Commun. 2008; 29: 39-44. (Pubitemid 351339339)
86. Blankenberg FG,. In vivo imaging of apoptosis. Cancer Biol. Ther. 2008; 7: 1525-32.
87. Boersma HH, Kietselaer BL, Stolk LM, et al,. Past, present, and future of annexin A5: from protein discovery to clinical applications. J. Nucl. Med. 2005; 46: 2035-50. (Pubitemid 46657451)
88. Reshef A, Shirvan A, Akselrod-Ballin A, et al,. Small-molecule biomarkers for clinical PET imaging of apoptosis. J. Nucl. Med. 2010; 51: 837-40.
89. Shirvan A, Reshef A, Allen A, et al,. Apoptosis imaging with PET-18F-ML-10 for early assessment of response of brain metastases to radiotherapy. J. Nucl. Med. Meet. Abstr. 2009; 50: 453.
90. Hoglund J, Shirvan A, Antoni G, et al,. 18F-ML-10, a PET tracer for apoptosis: first human study. J. Nucl. Med. 2011; 52: 720-5.
91. van Waarde A, Elsinga PH,. Proliferation markers for the differential diagnosis of tumor and inflammation. Curr. Pharm. Des. 2008; 14: 3326-39.
92. Hsieh HJ, Lin SH, Lin KH, et al,. The feasibility of 11C-methionine-PET in diagnosis of solitary lung nodules/masses when compared with 18F-FDG-PET. Ann. Nucl. Med. 2008; 22: 533-8.
93. Ishimori T, Saga T, Nagata Y, et al,. 18F-FDG and 11C-methionine PET for evaluation of treatment response of lung cancer after stereotactic radiotherapy. Ann. Nucl. Med. 2004; 18: 669-74. (Pubitemid 40215915)
94. Pauleit D, Stoffels G, Schaden W, et al,. PET with O-(2-18F-fluoroethyl)- L-tyrosine in peripheral tumors: first clinical results. J. Nucl. Med. 2005; 46: 411-16. (Pubitemid 43093148)
95. Kaira K, Oriuchi N, Otani Y, et al,. Fluorine-18-alpha-methyltyrosine positron emission tomography for diagnosis and staging of lung cancer: a clinicopathologic study. Clin. Cancer Res. 2007; 13: 6369-78. (Pubitemid 350075026)
96. Kaira K, Oriuchi N, Shimizu K, et al,. 18F-FMT uptake seen within primary cancer on PET helps predict outcome of non-small cell lung cancer. J. Nucl. Med. 2009; 50: 1770-6.
97. Pieterman RM, Que TH, Elsinga PH, et al,. Comparison of (11)C-choline and (18)F-FDG PET in primary diagnosis and staging of patients with thoracic cancer. J. Nucl. Med. 2002; 43: 167-72. (Pubitemid 34151038)
98. Khan N, Oriuchi N, Zhang H, et al,. A comparative study of 11C-choline PET and [18F]fluorodeoxyglucose PET in the evaluation of lung cancer. Nucl. Med. Commun. 2003; 24: 359-66.
99. Hofmann M, Maecke H, Borner R, et al,. Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data. Eur. J. Nucl. Med. 2001; 28: 1751-7.
100. Ambrosini V, Castellucci P, Rubello D, et al,. 68Ga-DOTA-NOC: a new PET tracer for evaluating patients with bronchial carcinoid. Nucl. Med. Commun. 2009; 30: 281-6.
101. van Dongen GA, Vosjan MJ,. Immuno-positron emission tomography: shedding light on clinical antibody therapy. Cancer Biother. Radiopharm. 2010; 25: 375-85.
102. Aerts HJ, Dubois L, Perk L, et al,. Disparity between in vivo EGFR expression and 89Zr-labeled cetuximab uptake assessed with PET. J. Nucl. Med. 2009; 50: 123-31.
103. Bury T, Paulus P, Dowlati A, et al,. Evaluation of pleural diseases with FDG-PET imaging: preliminary report. Thorax 1997; 52: 187-9. (Pubitemid 27086751)
104. Benard F, Sterman D, Smith RJ, et al,. Metabolic imaging of malignant pleural mesothelioma with fluorodeoxyglucose positron emission tomography. Chest 1998; 114: 713-22. (Pubitemid 28433730)
105. Orki A, Akin O, Tasci AE, et al,. The role of positron emission tomography/computed tomography in the diagnosis of pleural diseases. Thorac. Cardiovasc. Surg. 2009; 57: 217-21.
106. Erasmus JJ, Truong MT, Smythe WR, et al,. Integrated computed tomography-positron emission tomography in patients with potentially resectable malignant pleural mesothelioma: staging implications. J. Thorac. Cardiovasc. Surg. 2005; 129: 1364-70. (Pubitemid 40804856)
107. Ambrosini V, Rubello D, Nanni C, et al,. Additional value of hybrid PET/CT fusion imaging vs. conventional CT scan alone in the staging and management of patients with malignant pleural mesothelioma. Nucl. Med. Rev. Cent. East. Eur. 2005; 8: 111-15. (Pubitemid 43115961)
108. Benard F, Sterman D, Smith RJ, et al,. Prognostic value of FDG PET imaging in malignant pleural mesothelioma. J. Nucl. Med. 1999; 40: 1241-5. (Pubitemid 29385629)
109. Flores RM, Akhurst T, Gonen M, et al,. Positron emission tomography predicts survival in malignant pleural mesothelioma. J. Thorac. Cardiovasc. Surg. 2006; 132: 763-8. (Pubitemid 44415880)
110. Gerbaudo VH, Mamede M, Trotman-Dickenson B, et al,. FDG PET/CT patterns of treatment failure of malignant pleural mesothelioma: relationship to histologic type, treatment algorithm, and survival. Eur. J. Nucl. Med. Mol. Imaging 2011; 38: 810-21.
111. Nowak AK, Francis RJ, Phillips MJ, et al,. A novel prognostic model for malignant mesothelioma incorporating quantitative FDG-PET imaging with clinical parameters. Clin. Cancer Res. 2010; 16: 2409-17.
112. Lee HY, Hyun SH, Lee KS, et al,. Volume-based parameter of 18)F-FDG PET/CT in malignant pleural mesothelioma: prediction of therapeutic response and prognostic implications. Ann. Surg. Oncol. 2010; 17: 2787-94.
113. Byrne MJ, Nowak AK,. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann. Oncol. 2004; 15: 257-60. (Pubitemid 38262625)
114. Ceresoli GL, Chiti A, Zucali PA, et al,. Early response evaluation in malignant pleural mesothelioma by positron emission tomography with [18F]fluorodeoxyglucose. J. Clin. Oncol. 2006; 24: 4587-93. (Pubitemid 46630956)
115. Francis RJ, Byrne MJ, van der Schaaf AA, et al,. Early prediction of response to chemotherapy and survival in malignant pleural mesothelioma using a novel semiautomated 3-dimensional volume-based analysis of serial 18F-FDG PET scans. J. Nucl. Med. 2007; 48: 1449-58. (Pubitemid 47397395)
116. Veit-Haibach P, Schaefer NG, Steinert HC, et al,. Combined FDG-PET/CT in response evaluation of malignant pleural mesothelioma. Lung Cancer 2010; 67: 311-17.
117. Tsuji AB, Sogawa C, Sugyo A, et al,. Comparison of conventional and novel PET tracers for imaging mesothelioma in nude mice with subcutaneous and intrapleural xenografts. Nucl. Med. Biol. 2009; 36: 379-88.
118. Francis RJ, Segard T, Philips MJ, et al,. FLT PET imaging in malignant pleural mesothelioma (MPM). International Mesothelioma Interest Group Meeting Kyoto, Japan, 2010; 132.
119. Ceresoli GL, Chiti A, Santoro A,. 11C-labeled methionine and evaluation of malignant pleural mesothelioma. N. Engl. J. Med. 2007; 357: 1982-4. (Pubitemid 350074710)